Suven Pharmaceuticals Limited Fundamental Analysis (BSE: SUVENPHAR.BO)
Suven Pharmaceuticals Limited Fundamental Analysis (BSE: SUVENPHAR.BO)
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO) shows moderate financial fundamentals with a PE ratio of 91.13, profit margin of 28.56%, and ROE of 15.86%. The company generates $15.8B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 94.4/100 based on profitability, valuation, growth, and balance sheet metrics. The A grade reflects excellent fundamentals and strong overall stability.
Fundamental Health Score
We analyze SUVENPHAR.BO's fundamental strength across five key dimensions:
Efficiency Score
ExcellentSUVENPHAR.BO demonstrates superior asset utilization.
Valuation Score
ModerateSUVENPHAR.BO shows balanced valuation metrics.
Growth Score
ModerateSUVENPHAR.BO shows steady but slowing expansion.
Financial Health Score
ExcellentSUVENPHAR.BO maintains a strong and stable balance sheet.
Profitability Score
ExcellentSUVENPHAR.BO achieves industry-leading margins.
Key Financial Metrics
Is SUVENPHAR.BO Expensive or Cheap?
P/E Ratio
SUVENPHAR.BO trades at 91.13 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, SUVENPHAR.BO's PEG of -12.97 indicates potential undervaluation.
Price to Book
The market values Suven Pharmaceuticals Limited at 13.35 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 87.92 times EBITDA. This signals the market has high growth expectations.
How Well Does SUVENPHAR.BO Make Money?
Net Profit Margin
For every $100 in sales, Suven Pharmaceuticals Limited keeps $28.56 as profit after all expenses.
Operating Margin
Core operations generate 43.83 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $15.86 in profit for every $100 of shareholder equity.
ROA
Suven Pharmaceuticals Limited generates $13.32 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Suven Pharmaceuticals Limited generates strong operating cash flow of $5.39B, reflecting robust business health.
Free Cash Flow
Suven Pharmaceuticals Limited generates strong free cash flow of $4.61B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $12.05 in free cash annually.
FCF Yield
SUVENPHAR.BO converts 0.75% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
91.13
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-12.97
vs 25 benchmark
P/B Ratio
Price to book value ratio
13.35
vs 25 benchmark
P/S Ratio
Price to sales ratio
39.13
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.03
vs 25 benchmark
Current Ratio
Current assets to current liabilities
11.82
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.16
vs 25 benchmark
ROA
Return on assets percentage
0.13
vs 25 benchmark
ROCE
Return on capital employed
0.21
vs 25 benchmark
How SUVENPHAR.BO Stacks Against Its Sector Peers
| Metric | SUVENPHAR.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 91.13 | 29.15 | Worse (Expensive) |
| ROE | 15.86% | 492.00% | Weak |
| Net Margin | 28.56% | -11540.00% (disorted) | Strong |
| Debt/Equity | 0.03 | 0.79 | Strong (Low Leverage) |
| Current Ratio | 11.82 | 5.18 | Strong Liquidity |
| ROA | 13.32% | -130.00% (disorted) | Strong |
SUVENPHAR.BO outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Suven Pharmaceuticals Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation